close

Agreements

Date: 2012-04-18

Type of information: Collaboration agreement

Compound: fragment ligands that specifically bind to a Family B stabilised GPCR (StaR®) drug target purified by Heptares

Company: Selcia (UK) Heptares Therapeutics (UK)

Therapeutic area:

Type agreement:

collaboration

Action mechanism:

Disease:

Details:

Selcia and Heptares Therapeutics have entered into a new collaboration to discover fragment ligands that specifically bind to a Family B stabilised GPCR (StaR®) drug target purified by Heptares. This follows the successful conclusion of an initial proof-of-concept study using a Family A StaR®.
Selcia will initially develop a screening assay and then apply its novel CEfrag™ drug discovery technology to confirm hits already obtained by Heptares and to screen its proprietary fragment library against the Heptares target.
Selcia’s CEfrag™  platform utilises capillary electrophoresis technology to identify fragment compounds that selectively bind to drug targets. All reagents are in solution and no tethering of the protein is required, enabling near physiological ligand/target interactions to be observed with a low false positive rate. As well as stabilised GPCRs, CEfrag™ can be used to detect fragment/target interactions across a wide range of other target classes including “challenging” targets such as protein-protein interactions.

Financial terms:

Latest news:

Is general: Yes